The PFA system earned expanded labeling in Europe to include the treatment of persistent AFib, according to a LinkedIn post.

“This approval represents an important step forward in addressing the evolving needs of the millions affected by persistent [AFib] across Europe, enhancing our ability to provide innovative solutions that improve patient outcomes,” the account for Boston Scientific’s Cardiology unit posted.